产品名称 | NebuSelect™ Recombinant Human LYPD3, His-tag |
---|---|
目录号 | NBL-242334 |
别名 | LYPD3; MIG-C4; LYPD3; C4.4A; LY6/PLAUR domain containing 3 |
外观 | see COA |
分子量 | |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | O95274 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242334-100ug | 100ug | Inquire | Inquire | |
NBL-242334-1mg | 1mg | Inquire | Inquire | |
NBL-242334-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human LYPD3, His-tag
Catalog#:
NBL-242334
Description:
NebuSelect™ Recombinant Human LYPD3, His-tag(Cat#NBL-242334) is expressed in HEK293 with His tag at the C-Terminus.It contains Leu31-His286.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 27.8 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
Target Name:
LYPD3; MIG-C4; LYPD3; C4.4A; LY6/PLAUR domain containing 3
Target Information:
Aberrant expression of LYPD3 plays an oncogenic role in several types of cancer. LYPD3 was highly expressed in LUAD tumor compared with paracancerous tissues.Furthermore, the expression of LYPD3 was able to be regulated by the methylation in LYPD3 promoter region, which was positively associated with the overall survival. LYPD3 might affect the clinical manifestations of LUAD by regulating the P53 signaling pathway.
Amino Acid Sequence:
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.